More stories
Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA...
Words by Josh Hardman. *** We have barely kicked off 2025 and already a handful of ketamine-related news stories have emerged. In this ketamine-focused...
Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to...
Earlier this week, The New York Times published a story that, above all, suggests that Psymposia was substantially to blame for FDA’s August rejection...
How Psychedelics Impact the Mind: Mysticism, Mental Health, and the Future of Psychedelic Research
Psychedelic research is growing rapidly, but how do we study something as subjective as a mystical experience? In this episode, Joe interviews Josh Lipson,...
GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression
Words by Josh Hardman, reviewed by Medical Advisor Michael Haichin. *** This morning, Irish 5-MeO-DMT drug developer GH Research shared topline data from its...
2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis
Since the start of the 2025 legislative session, more than three dozen psychedelics-related bills have been introduced across more than a dozen states. That...
Psychedelic Drug Development Pipeline Updates (Q1’25)
This review of significant changes, additions, and removals to the Bullseye Chart is exclusively for Pα+ subscribers. If you’re not yet a subscriber, you...
Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart
Q1’25 BULLSEYE CHART We map our Q1’25 Psychedelics Drug Development Tracker data onto a ‘bullseye chart’ format. Given the number of candidates included, we...
How Do You Find the Right Facilitator? The Art of Matchmaking in Psychedelic Healing
More and more people are looking to have psychedelic experiences every day, but what do you do if you don’t know who to go...
Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear;...
Google co-founder Sergey Brin was given a prominent spot on the seating arrangement for Trump’s inauguration on Monday. He was sat among fellow billionaires...
Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes Back on State...
Here, we take a look at Compass Pathways’ lobbying agenda, with a particular focus on a Colorado bill that the company is backing, as...
Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC
In this episode, Joe interviews renowned chemist, filmmaker, and journalist, Hamilton Morris. After originally backing down from its first attempt in 2022, the DEA...
